3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Thrombocytopenia
3
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Leukemia, Myeloid, Acute
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Interventions
Cyclophosphamide
22
fludarabine phosphate
18
Busulfan
16
Antilymphocyte Serum
15
Radiotherapy
12
Cyclosporine
11
Cord Blood Stem Cell Transplantation
11
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
Filgrastim
10
Tacrolimus
9
Mycophenolic Acid
9
Methylprednisolone
9
Methotrexate
9
Etoposide
7
Cytarabine
7
Whole-Body Irradiation
6
sargramostim
4
Tretinoin
3
Thalidomide
3
Carboplatin
3
venetoclax
2
ruxolitinib
2
Thiotepa
2
Thioguanine
2
Specimen Handling
2
Sirolimus
2
Rituximab
2
Leucovorin
2
Immunoenzyme Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic-Myeloproliferative Diseases
×
Tranexamic Acid
×
Classical hematology
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled